Published in Transplantation on January 27, 1995
Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest (2010) 3.59
The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81
Transplantation tolerance from a historical perspective. Nat Rev Immunol (2001) 2.04
The saga of liver replacement, with particular reference to the reciprocal influence of liver and kidney transplantation (1955-1967). J Am Coll Surg (2002) 1.81
Weaning of immunosuppression in liver transplant recipients. Transplantation (1997) 1.57
Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: durable chimerism predicts outcome. Transplantation (2013) 1.50
Lessons of organ-induced tolerance learned from historical clinical experience. Transplantation (2004) 0.94
Risks and benefits of weaning immunosuppression in liver transplant recipients: long-term follow-up. Transplant Proc (1997) 0.92
Augmentation of natural chimerism with donor bone marrow in orthotopic liver recipients. Transplant Proc (1996) 0.90
Liver tolerance mediated by antigen presenting cells: fact or fiction? Gut (2003) 0.89
Distinct response of liver myeloid dendritic cells to endotoxin is mediated by IL-27. J Hepatol (2009) 0.88
Transplantation of primary and reversibly immortalized human liver cells and other gene therapies in acute liver failure and decompensated chronic liver disease. World J Gastroenterol (2000) 0.87
HLA-G level on monocytoid dendritic cells correlates with regulatory T-cell Foxp3 expression in liver transplant tolerance. Transplantation (2011) 0.86
Human hepatic stellate cells inhibit T-cell response through B7-H1 pathway. Transplantation (2013) 0.84
Long-term management of immunosuppression after pediatric liver transplantation: is minimization or withdrawal desirable or possible or both? Curr Opin Organ Transplant (2008) 0.83
Microchimerism: inaccurate literature citations. Transplantation (1996) 0.80
Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts. Ann Transplant (1997) 0.79
Transplantation tolerance. Pediatr Nephrol (2013) 0.78
Management of immunosuppressant agents following liver transplantation: Less is more. World J Hepatol (2016) 0.78
Hepatic and intestinal transplantation at the University of Pittsburgh. Clin Transpl (1998) 0.78
The two-way paradigm of transplantation immunology. Clin Immunol Immunopathol (1996) 0.78
Pancreas and islet cell transplantation. Best Pract Res Clin Gastroenterol (2002) 0.78
BIOMARKERS OF OPERATIONAL TOLERANCE IN SOLID ORGAN TRANSPLANTATION. Expert Opin Med Diagn (2012) 0.77
Liver transplant tolerance and its application to the clinic: can we exploit the high dose effect? Clin Dev Immunol (2013) 0.76
Organ-specific differences in achieving tolerance. Curr Opin Organ Transplant (2015) 0.76
Hepatic transplantation at the University of Pittsburgh: new horizons and paradigms after 30 years of experience. Clin Transpl (1994) 0.76
The current status of hepatic transplantation at the University of Pittsburgh. Clin Transpl (1995) 0.76
Expression of alpha smooth muscle actin in living donor liver transplant recipients. World J Gastroenterol (2014) 0.76
The birth of clinical organ transplantation. J Am Coll Surg (2001) 0.76
Hepatic Stellate Cells Directly Inhibit B Cells via Programmed Death-Ligand 1. J Immunol (2016) 0.75
Prevention of Transplant Rejection: Can Tolerance be Achieved with Immunosuppressive Treatment? Clin Immunother (1996) 0.75
A randomised controlled trial of total immunosuppression withdrawal in stable liver transplant recipients. Gut (2007) 0.75
Establishment of a new pig model for auxiliary partial orthotopic liver transplantation. World J Gastroenterol (2005) 0.75
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29
Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39
The hepatotropic influence of cyclosporine. Surgery (1990) 2.27
Transplantation milestones. Viewed with one- and two-way paradigms of tolerance. JAMA (1995) 2.20
Split tolerance induced by orthotopic liver transplantation in mice. Transplantation (1994) 1.52
Spontaneous and iatrogenically augmented leukocyte chimerism in organ transplant recipients. Transplant Proc (1994) 1.29
Immunological monitoring of long-surviving renal transplant recipients. Surgery (1977) 1.25
Failure of in vitro assays to predict accurately the existence of neonatally induced H-2 tolerance. Transplantation (1989) 1.25
Cell-mediated lympholysis studies in renal allograft recipients. Transplantation (1981) 1.25
Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology (1994) 1.14
Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation. Am J Surg Pathol (1995) 1.08
Frequent achievement of a drug-free state after orthotopic liver transplantation. Transplant Proc (1993) 1.08
Weaning of immunosuppression in long-term recipients of living related renal transplants: a preliminary study. Transplant Proc (1995) 0.99
A new in vitro approach to determine acquired tolerance in long-term kidney allograft recipients. Transplantation (1990) 0.96
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24
The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Kidney transplantation under FK 506. JAMA (1990) 7.45
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
The portal circulation: I. The action of adrenaline and pituitary pressor extract. J Physiol (1932) 6.88
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg (1989) 5.78
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96
Liver transplantation (1). N Engl J Med (1989) 4.53
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92
Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85
Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Transplantation of multiple abdominal viscera. JAMA (1989) 3.59
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40
Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26
The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
Renal transplantation in baboons under FK 506. Surgery (1989) 3.17
Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol (1985) 3.16
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13
Orthotopic liver transplantation in dogs receiving FK-506. Transplant Proc (1987) 3.11
A multifactorial system for equitable selection of cadaver kidney recipients. JAMA (1987) 3.01
Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med (1992) 2.98
Biliary tract complications in human orthotopic liver transplantation. Transplantation (1987) 2.95
Outcome analysis of 71 clinical intestinal transplantations. Ann Surg (1995) 2.95
Liver transplantation (2). N Engl J Med (1989) 2.93
Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res (1997) 2.91
Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91
Equitable allocation of extrarenal organs: with special reference to the liver. Transplant Proc (1988) 2.85
Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84
Allospecificity of activated T cells grown from endomyocardial biopsies from heart transplant patients. Transplantation (1986) 2.82
The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81
Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81
Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75
The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med (1995) 2.68
A review of adult and pediatric post-transplant liver pathology. Pathol Annu (1987) 2.62
Management of intestinal transplantation in humans. Transplant Proc (1992) 2.62
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59
The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology (1997) 2.57
CARDIAC CATHETERIZATION IN CASES OF PATENT INTERAURICULAR SEPTUM, PRIMARY PULMONARY HYPERTENSION, FALLOT'S TETRALOGY, AND PULMONARY STENOSIS. Br Heart J (1947) 2.57
FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50